Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of$ 0.45. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.50 per share when it actually produced a loss of $0.43, delivering a surprise of 14%.Over the last four quarters, t ...